Journal of Inflammation Research

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Neurodegenerative Diseases: From Pathogenesis to Treatment" in the Journal of Inflammation Research.

Neurodegenerative diseases are chronic disorders corroborated with central nervous system damage. They are characterized by the loss of neurons resulting in neuropsychomotor dysfunctions. Some of these disorders which will be discussed in this Article Collection include Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, globoid cell leukodystrophy, and amyotrophic lateral sclerosis.

Alzheimer's disease is a progressive neurodegenerative disorder characterized by the deposition of senile plaques containing amyloid β (Aβ), albeit how the peptide induces neurotoxicity is not clear.

Huntington's disease involves progressive degeneration of neurons in the striatum and cerebral cortex resulting in loss of control of motor function leading to cognitive dysfunction.

Parkinson's disease is characterized by α-synuclein accumulation, dopaminergic neuron loss and inflammation. Pathological α-synuclein and microglial activation can potentiate each other, leading to the loss of dopaminergic neurons and accelerated the disease degeneration.

Multiple sclerosis is a chronic inflammatory demyelinating disease of the central nervous system that affects several million patients worldwide.

Globoid cell leukodystrophy (also known as Krabbe disease) is a rare autosomal recessive disease that affects infants. Patients who are homozygous for this disease die before the age of two years from hyperpyrexia or respiratory infections.

Amyotrophic lateral sclerosis is another rare, fatal disorder characterized by loss of upper and lower motor neurons, resulting in progressive weakness of all voluntary muscles and eventual respiratory failure.

The pathology and/or etiology of these diseases are still unresolved and require further investigations.

Although neurodegenerative diseases have high prevalence worldwide, the diseases are only treated with drugs that alleviate the symptoms of patients. Consequently, they do not cure the neurodegenerative diseases and can only improve the quality of patients’ lives. Drugs developed to treat these diseases are mainly pleotropic, and their mechanisms of action (MOA) differ among patients and among diseases. Further, they may develop adverse reactions, yet do not inhibit the progression of the diseases.

This Article Collection will focus on new therapeutic modalities to treat neurodegenerative diseases; modalities that may module the immune system in these pathologies. In addition, the Article Collection will discuss other therapeutic modalities such as cognitive therapy. We welcome the submission of original research articles, reviews, and mini-review articles.

Topics of Interest Include:

1. Novel understandings of the pathogenesis of neurodegenerative diseases.
2. Development of new drugs and monoclonal antibodies that target inflammation with the aim of treating and/or preventing neurodegenerative disorders in humans or in mouse models.
3. Exploring the values of other therapeutic modalities such as cognitive therapy or physiotherapy, among others.
4. Implementing the concept and methods of artificial intelligence (AI) in investigating and resolving issues related to neurodegenerative disorders.

Guest Advisor

Prof. Azzam A. Magazachi, University of Sharjah, Sharjah, UAE

Dr. Maghazachi's main research interests are immunotherapy of cancer using natural killer (NK) cells, autoimmune diseases with emphasis on multiple sclerosis and rheumatoid arthritis, chemokines, and drug mechanisms of action. He was the first to identify all chemokine receptors, lysophospholipids and oxidized lipids receptors on NK cells. He has collaborated with major pharmaceutical companies such as TEVA and Biogen to examine the biological activities of their drugs Copaxone and Tecfidera, respectively, on NK cells, and holds a patent on the effects of dimethyl fumarate and monomethyl fumarate in the therapy of cancer. He is the editor or editor-in-chief of more than 15 scientific journals in the fields of Immunology, Toxicology, and Neuroscience. He has published more than 120 scientific papers as well as book chapters and ebooks.

Submission Instructions:

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisor will not be handling the manuscripts. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

During submission, enter the promo code VRXME to indicate that your submission should be considered for this Collection.

The deadline for submitting manuscripts is 1 October 2023. If you have questions, please contact Krista Thom at [email protected].

Instructions for AuthorsSubmit an Article